Agilent Technologies Inc. (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water Research Institute (NEWRI), outlining their collaboration in advancing environmental and water research over the next three years.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Australian molecular diagnostics developer Genetic Signatures has signed a strategic partnership with lab automation solutions provider Tecan and in vitro diagnostic software developer Repado. Announced on Tuesday, the partnership aims to create a scalable suite of fully integrated syndromic infectious disease testing systems. Financial terms were not disclosed.

The University of California, Los Angeles School of Dentistry and South Korean semiconductor firm Dongwoon Anatech said on Friday that they have inked a three-year agreement worth upward of $2.4 million for the development of saliva-based liquid biopsy technologies.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed.

QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Personalis said this week that it has extended its strategic collaboration with Tempus AI to include colorectal cancer (CRC) among the indications covered by their existing, exclusive commercialization agreement.

Claret Bioscience, a pioneer in next-generation sequencing (NGS) library preparation technologies for challenging samples, and Hamilton Company, a global leader in precision laboratory automation, are proud to announce a strategic co-promotion initiative. This collaboration aims to accelerate and simplify workflows for throughput NGS library preparation by delivering validated automation protocols for ClaretBio’s SRSLY® and REALLY™ product lines on Hamilton’s NGS STAR liquid handling platforms.